Cell Based Screening in Drug Discovery 2022

Posters

Thomas Hochdörfer
AstraZeneca
Sweden
1Compound Screening in Peripheral Blood Mononuclear Cells via Cell Painting
Nathalie Brandenberg
SUN bioscience SA
Switzerland
2A standardized and automated screening workflow for targeted chemotherapy assessment in human pancreatic cancer organoids
Anke Loregger
Myllia Biotechnology
Austria
3Single-cell CRISPR screens in primary human T cells
Tove Selvin
Uppsala universitet
Sweden
4Phenotypic screening platform identifies statins as enhancers of immune cell-dependent cancer elimination
Nadine Dahm
F Hoffman La Roche AG
Switzerland
5Upscaling qPCR for small molecule screening of RNA targets
Olivier Frey
InSphero AG
Switzerland
63D-optimized 384-well microplate for spheroid production, high-resolution imaging, and an automated workflow in a single plate
Katherine Czysz
Fujifilm Cellular Dynamics, Inc.
7ESTABLISHMENT OF A BLOOD-BRAIN BARRIER MODEL USING IPSC-DERIVED HUMAN CELLS
Giorgia Salvagiotto
FUJIFILM Cellular Dynamics
United States
8Establishment of iPSC-derived “brain-in-a-dish” tri-culture models
Cafer Yıldırım
Eskisehir Osmangazi University
Turkey
9Cell Screening base of the Analgesic and Anti-inflammatory Effects of Safflower Oil
Przemek Fleszar
Molecular Devices (UK) Ltd
10Lung organoids as an assay model for in vitro assessment of toxicity effects by 3D high-content imaging and analysis
Sofie Devacht
Merck
Belgium
11Enhancing well-to-well reproducibility of colon organoids for screening applications
Hannah Rowlands
AstraZeneca
12Adapting a HiBiT CETSA® assay for High Throughput Screening
Tiziana Monteverde
AstraZeneca
13Cell Painting enables morphological profiling of PROTACs for mitotoxicity prediction
Sian Gardiner
Cardiff University
14Developing a robust vATPase activity assay to identify novel therapies for Alzheimer disease
Jonne Rietdijk
Uppsala University
Sweden
15Exploring combination effects of environmental chemicals by morphological profiling
Amelie Wenz
Uppsala University
Sweden
16 Morphological Cell Profiling for Drug Discovery with Medical Applications
Bora Baskaner
Pelago Bioscience AB
Sweden
17CETSA®EXPLORE: Target Engagement Profiles to Study SAR, Off-Targets, and Toxicity at Proteome Wide Level
Åke Jägervall
Cellectricon
Sweden
18A NaV1.2 modulator discovery program for treatment of SCN2A-related disorders such as autism spectrum disorder and intellectual disability
Adelinn Kalman
ScilifeLab
Sweden
19Exploring the morphology of the host cell to open new possibilities in drug repurposing
Lydia Aschauer
Orbit Discovery
20Generating Novel Peptide Leads against the Melanocortin 4 Receptor using the Orbit Display Platform
Sun Yung
Nexcelom from PerkinElmer
United States
21Large-Batch Evaluation of Cell Counter Instrument-to-Instrument Consistency for Cell Therapy Applications
Suzanne Riches
Nexcelom from PerkinElmer
United States
22Large-Batch Evaluation of Cell Counter Instrument-to-Instrument Consistency for Cell Therapy Applications
Pia Hansson
AstraZeneca
Sweden
23AlphaLISA protein level analysis for ASO and PROTAC discovery
Pontus Forsell
AlzeCure Pharma
Sweden
24The use of PathHunter cell lines to discover modulators of Trk-receptors. From screen to phase 1
Andreas Nolting
Attana AB
Sweden
25Application of Attana Cell-based QCM Interaction studies in Drug Discovery
Jianming Liu
AstraZeneca R&D
Sweden
26Development of a novel sandwich ELISA in 384w format to detect Histone 3.3
Martin Melovic
Axion BioSystems
Sweden
27Kinetics and potency of T Cell- and CAR-T Cell-mediated cytolysis of glioma stem cells
Massimiliano Gaetani
Karolinska Institute
Sweden
28Current Advances in PISA (Proteome Integral Solubility Alteration) Assay for Proteome-Wide, MS-based, Deep, High Throughput, and High Confidence Drug Target Identification and Mechanism of Action Elucidation
Kris Rutten
WuXi AppTec
29The critical platforms of PROTAC validation
Greta Gudoityte
Karolinska Institutet
Sweden
30Impact of Cancer-Associated Fibroblasts on Ovarian Cancer Cell Proliferation and Drug Response Revealed by Live-Cell Imaging
Guy Williams
AstraZeneca
31JUMP-CP at AstraZeneca: Creating the World’s Largest Cell Painting Dataset
Swapnil Potdar
University of Helsinki
Finland
32SPECSPortal: An interactive web portal to visualize drug screening data generated from SPECS panel for drug repurposing.
Joan Mir Coll
InSphero
Switzerland
33Low-throughput AAV serotype screen in human islet microtissues for scalable and efficient genetic modification
Linnea Kristenson
Göteborgs Universitet
Sweden
34Genome-Wide CRISPR screen identifies TMEM30A as a key regulator of NK cell cytotoxicity
Christa Ringers
University of Uppsala
Sweden
35Cell Painting to capture colorectal cancer disease heterogeneity.
Antonia Konczwald
Beckman Coulter Life Sciences
Germany
36Organoids for disease modeling and in vitro drug screening: Automated culture monitoring, imaging, and analysis of complex biological systems
Bertille Boudier
bit.bio
37MODELLING NEURODEGENERATION USING A HUMAN ISOGENIC SYSTEM: A NEXT GENERATION APPROACH TO STUDY HUNTINGTON'S DISEASE
Carlo Zaniol
PerkinElmer AB
Sweden
38Novel HTRF platform to delineate molecular mechanisms of STING pathway modulators
Anna-Lena Gustavsson
Karolinska Institute
Sweden
39The Chemical Biology Consortium Sweden
Bernhard Schmierer
SciLifeLab and Karolinska Institutet
Sweden
40SciLifeLab CRISPR Functional Genomics and Karolinska Genome Engineering: Open access to advanced CRISPR technologies
Abbie Macmillan-Jones
AstraZeneca
41A novel process for development of high-throughput cell-based screening assays against transport proteins
Linda Kitching
AstraZeneca
42Development of high throughput compatible minigene screening assays to identify small molecules that induce exon skipping
Count: 42



Sponsor